GSK has agreed to pay Hutchmed $110 million upfront for rights to HMPL-A830, an experimental cancer drug aimed at solid tumors. The deal gives GSK worldwide rights outside Mainland China, Hong Kong, Macau and Taiwan. HMPL-A830 is described as a first-in-class KRAS-EGFR antibody-targeted therapy conjugate, with initial development focused on colorectal, pancreatic and lung cancers. Hutchmed could receive up to about $1.295 billion in total, including up to $1.185 billion in development, regulatory and commercial milestones, plus tiered royalties. Hutchmed will retain rights in Greater China and lead the global Phase I trial, expected to start in the second half of 2026. The agreement is subject to customary closing conditions, including antitrust review. Sources: GSK agrees to pay $110 million for HUTCHMED cancer-drug rights Hutchmed China inks USD1.30 billion GSK deal for cancer drug ... GSK bets USD 1.3b on HutchMed's KRAS-EGFR conjugate Hutchmed Enters Licensi...
- Get link
- X
- Other Apps